{"organizations": [], "uuid": "2d0aeda2b0ad07ef884373ca0698072e5c7561da", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-zafgen-to-host-conference-call-to-discuss-first-quarter-2018-financial-results.html", "country": "US", "domain_rank": 767, "title": "Zafgen to Host Conference Call to Discuss Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.06, "site_type": "news", "published": "2018-05-02T00:30:00.000+03:00", "replies_count": 0, "uuid": "2d0aeda2b0ad07ef884373ca0698072e5c7561da"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-zafgen-to-host-conference-call-to-discuss-first-quarter-2018-financial-results.html", "ord_in_thread": 0, "title": "Zafgen to Host Conference Call to Discuss Financial Results", "locations": [], "entities": {"persons": [{"name": "zafgen zafgen", "sentiment": "none"}], "locations": [{"name": "zafgen", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its first quarter ended March 31, 2018.\nParticipants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 6639039. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations . A replay of this conference call will be available beginning at 7:30 p.m. ET on May 8, 2018 through May 15, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 6639039.\nAbout Zafgen\nZafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The companyâ€™s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com .\nMedia/Investor Relations Contacts :\nZafgen, Inc.\nPatricia Allen\nChief Financial Officer\n617-648-9792\nMedia\nKrystle Gibbs\nTen Bridge Communications\nkrystle@tenbridgecommunications.com\n508-479-6358\nInvestors\nJohn Woolford\nWestwicke Partners\nJohn.woolford@westwicke.com\n443-213-0506\nSource:Zafgen, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=zDcZnTb4prpTAn-0_8Vi4QKdPxj5tpoh1rjGZl0FJMuB6US6Raof2ln8IJQFwPs-Sa9mGuwMrmc7dc59UQ4t4A==", "https://www.globenewswire.com/Tracker?data=tFtJMdL87udv3fvSYfzRWlrzCmHY5HbTIzosqzE88RCRWOjbaivZ4oIEylsfRj2LKuqGYpKoaX6jRjzuvbYCd9F_3U0W5f1Mux3kA2mDb0jH3HZQ_hY43_horZGZSqyahHkG5LvLMLu-PodecMmOtg==", "https://www.globenewswire.com/Tracker?data=vAeahFFuBIP5PrCFqH4NgS_jcmC7SKwcNWLV3-3XPf1Ye7suJqaGZM3TWdQBr5mSAsd8zwgXd6yEoXCF2McsemG-4u26hc0ueyqvTju4jv2_EiBuY8ELctuUzqK0uVh9", "https://www.globenewswire.com/NewsRoom/AttachmentNg/ee4d8e02-e39f-4e10-a617-f5bc5ec8aea6", "https://zafgen.gcs-web.com/events-and-presentations", "https://www.globenewswire.com/Tracker?data=dbwe62fpF-G1QZZwu8bnDwpkbcyJ0DSloTT40-l6wP4_Bvn1a7Q7GEV3uQ3bFlg5t_lmkjrKaqyUo0GqyYGfZyl7Mu3Hnl3-KWgAPTfeK7bN1knywUoNjt4SJS70dzjHjpnuc6TV1-bxzsstg_fpMYGLt4yT3yquoAtfhHB6NzE="], "published": "2018-05-02T00:30:00.000+03:00", "crawled": "2018-05-02T02:49:46.013+03:00", "highlightTitle": ""}